DK0616812T3 - Kombination af antihormonforbindelser og bindingsmolekyler til behandling af cancer - Google Patents

Kombination af antihormonforbindelser og bindingsmolekyler til behandling af cancer

Info

Publication number
DK0616812T3
DK0616812T3 DK93250090T DK93250090T DK0616812T3 DK 0616812 T3 DK0616812 T3 DK 0616812T3 DK 93250090 T DK93250090 T DK 93250090T DK 93250090 T DK93250090 T DK 93250090T DK 0616812 T3 DK0616812 T3 DK 0616812T3
Authority
DK
Denmark
Prior art keywords
combination
antihormone
compounds
binding molecules
treat cancer
Prior art date
Application number
DK93250090T
Other languages
English (en)
Inventor
Beatrice C Langton
Original Assignee
Berlex Biosciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8214259&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0616812(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Berlex Biosciences filed Critical Berlex Biosciences
Application granted granted Critical
Publication of DK0616812T3 publication Critical patent/DK0616812T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DK93250090T 1993-03-24 1993-03-24 Kombination af antihormonforbindelser og bindingsmolekyler til behandling af cancer DK0616812T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP93250090A EP0616812B1 (en) 1993-03-24 1993-03-24 Combination with anti-hormonal compounds and binding molecules for the treatment of cancer

Publications (1)

Publication Number Publication Date
DK0616812T3 true DK0616812T3 (da) 2000-04-25

Family

ID=8214259

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93250090T DK0616812T3 (da) 1993-03-24 1993-03-24 Kombination af antihormonforbindelser og bindingsmolekyler til behandling af cancer

Country Status (7)

Country Link
EP (1) EP0616812B1 (da)
AT (1) ATE186219T1 (da)
DE (1) DE69326937T2 (da)
DK (1) DK0616812T3 (da)
ES (1) ES2141128T3 (da)
GR (1) GR3032511T3 (da)
PT (1) PT616812E (da)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
DE69839942D1 (de) 1997-10-29 2008-10-09 Genentech Inc Verwendung des wnt-1 induzierten sekretierten polypeptids wisp-1
CA2306450C (en) 1997-10-29 2012-07-10 Genentech, Inc. Polypeptides and nucleic acids encoding same
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
ES2305608T3 (es) 1997-11-21 2008-11-01 Genentech, Inc. Antigenos tipo a-33 y sus utilizaciones farmacologicas.
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
EP1947119A3 (en) 1997-12-12 2012-12-19 Genentech, Inc. Treatment of cancer with anti-erb2 antibodies in combination with a chemotherapeutic agent
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
ES2389387T3 (es) 1998-03-17 2012-10-25 Genentech, Inc. Polipéptidos homólogos de VEGF y de BMP1
WO2001060397A1 (en) 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
CA2450402A1 (en) 1998-12-22 2000-06-29 Genentech, Inc. Methods and compositions for inhibiting cancer cell growth comprising pro224
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
BR122014028365B8 (pt) 1999-06-25 2021-07-06 Genentech Inc artigo industrializado compreendendo um primeiro recipiente que compreende uma composição de humab4d5-8 nele contida e um segundo recipiente que compreende uma composição rhumab 2c4 nele contida
HU230586B1 (hu) 1999-06-25 2017-02-28 Genentech, Inc. Anti-ErbB antitest/maytansinoid konjugátumok alkalmazása rákos betegségek kezelésére szolgáló gyógyszer előállítására
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
DE60042693D1 (de) 1999-08-27 2009-09-17 Genentech Inc Dosierung für die behandlung mit anti erbb2-antikörpern
DK1897944T3 (da) 1999-12-23 2011-10-24 Genentech Inc IL-17 homologe polypeptider og terapeutisk anvendelse deraf
JP2003519491A (ja) 2000-01-13 2003-06-24 ジェネンテック・インコーポレーテッド 新規なｓｔｒａ６ポリペプチド
JP2003534292A (ja) 2000-05-19 2003-11-18 ジェネンテック・インコーポレーテッド Ｅｒｂｂアンタゴニスト癌治療に対する有効な応答の可能性を向上させるための遺伝子検出アッセイ
EP2042597B1 (en) 2000-06-23 2014-05-07 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
CA2709771A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
CA2633171C (en) 2001-06-20 2012-11-20 Genentech, Inc. Antibodies against tumor-associated antigenic target (tat) polypeptides
NZ573831A (en) 2001-09-18 2010-07-30 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor, particularly breast tumor - TAT193
KR20080106369A (ko) 2002-01-02 2008-12-04 제넨테크, 인크. 종양의 진단 및 치료 방법 및 이를 위한 조성물
WO2003072035A2 (en) 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
ES2429112T3 (es) 2002-04-10 2013-11-13 Genentech, Inc. Variantes de anticuerpos anti-HER2
KR20040101502A (ko) 2002-04-16 2004-12-02 제넨테크, 인크. 종양의 진단 및 치료 방법 및 이를 위한 조성물
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
EP1553912A4 (en) 2002-06-07 2007-08-08 Genentech Inc COMPOSITIONS AND METHODS FOR TUMOR DIAGNOSIS AND TREATMENT
AU2003247806B2 (en) 2002-07-08 2009-11-12 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
MXPA05000403A (es) 2002-07-15 2005-07-22 Genentech Inc Metodos para identificar tumores que responden al tratamiento con anticuerpos contra erbb2.
EP2277532A1 (en) 2002-09-11 2011-01-26 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
AU2003276874B2 (en) 2002-09-11 2009-09-03 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
EP2116616A3 (en) 2002-09-11 2010-03-17 Genentech, Inc. Genes differentially expressed in activated T cells and uses thereof
CA2498274A1 (en) 2002-09-16 2004-03-25 Genentech, Inc. Compositions and methods for the diagnosis of immune related diseases using pro7
CA2499843A1 (en) 2002-09-25 2004-04-08 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
EP2322203A3 (en) 2002-10-29 2011-07-27 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
AU2003295401B2 (en) 2002-11-08 2010-04-29 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
EP2314676A1 (en) 2002-11-26 2011-04-27 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2519241A1 (en) 2003-04-01 2004-11-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
ATE516047T1 (de) 2003-05-09 2011-07-15 Diadexus Inc Ovr110-antikörperzusammensetzungen und anwendungsverfahren
EP1641822B1 (en) 2003-07-08 2013-05-15 Genentech, Inc. Il-17 a/f heterologous polypeptides and therapeutic uses thereof
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
NZ596981A (en) 2003-11-17 2013-10-25 Genentech Inc Compositions and methods for the treatment of tumor of hematopoietic origin
AU2005232657B2 (en) 2004-04-08 2010-12-16 David B. Agus ErbB antagonists for pain therapy
NZ580115A (en) 2004-09-23 2010-10-29 Genentech Inc Cysteine engineered antibody light chains and conjugates
AU2005304462B2 (en) 2004-11-10 2011-03-10 Diadexus, Inc. Ovr110 antibody compositions and methods of use
US7964195B2 (en) 2005-01-07 2011-06-21 Diadexus, Inc. Ovr110 antibody compositions and methods of use
US7449184B2 (en) 2005-01-21 2008-11-11 Genentech, Inc. Fixed dosing of HER antibodies
PT1850874E (pt) 2005-02-23 2013-12-02 Genentech Inc Extensão de tempo até a progressão da doença ou sobrevivência em pacientes com cancro de ovário usando pertuzumab
MX2007010922A (es) 2005-03-10 2007-10-12 Genentech Inc Metodos y composiciones para modular la integridad vascular.
US7858843B2 (en) 2005-06-06 2010-12-28 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
CA2619577A1 (en) 2005-08-15 2007-02-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
AU2006335053A1 (en) 2005-11-21 2007-07-19 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
JP2009518314A (ja) 2005-12-02 2009-05-07 ジェネンテック・インコーポレーテッド Ｉｌ−２２に結合する抗体およびｉｌ−２２ｒに結合する抗体を含む、サイトカインシグナリングに関連する疾患および障害の処置のための組成物および方法
EP1988768A2 (en) 2006-02-17 2008-11-12 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
EP2389948A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
AU2007297565A1 (en) 2006-04-19 2008-03-27 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
CA2670696A1 (en) 2006-11-27 2008-06-05 Diadexus, Inc. Ovr110 antibody compositions and methods of use
PE20090681A1 (es) 2007-03-02 2009-06-10 Genentech Inc Prediccion de respuesta a un inhibidor her
CA2690334C (en) 2007-06-08 2017-02-14 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
PE20140614A1 (es) 2007-07-16 2014-05-28 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados
CA2692819A1 (en) 2007-07-16 2009-01-22 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
GB2453589A (en) 2007-10-12 2009-04-15 King S College London Protease inhibition
AR070141A1 (es) 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
SI2247620T1 (sl) 2008-01-31 2016-09-30 Genentech, Inc. Protitelesa proti CD79b in imunokonjugati in postopki za uporabo
MX364200B (es) 2008-04-09 2019-04-16 Genentech Inc Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
RU2553517C2 (ru) 2008-05-06 2015-06-20 Дженентек, Инк. Варианты crig с созревшей аффинностью
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
JP6067222B2 (ja) 2008-07-15 2017-01-25 ジェネンテック， インコーポレイテッド アントラサイクリン誘導体コンジュゲート、その調製方法及び抗腫瘍化合物としてのその用途
ES2572728T3 (es) 2009-03-20 2016-06-02 F. Hoffmann-La Roche Ag Anticuerpos anti-HER biespecíficos
CN102471380B (zh) 2009-04-01 2015-01-14 霍夫曼-拉罗奇有限公司 抗FcRH5抗体和免疫偶联物及使用方法
JP5705836B2 (ja) 2009-05-29 2015-04-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ２を発現する胃癌患者のｈｅｒ２シグナル伝達のためのモジュレーター
AU2010292172A1 (en) 2009-09-09 2012-05-03 Centrose, Llc Extracellular targeted drug conjugates
WO2011050194A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
CN103724432B (zh) 2009-11-30 2016-06-08 霍夫曼-拉罗奇有限公司 治疗和诊断表达slc34a2(tat211=seqid2)的肿瘤的抗体
CA2781682A1 (en) 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
US20110159588A1 (en) 2009-12-30 2011-06-30 Kui Lin Methods for Modulating a PDGF-AA Mediated Biological Response
US9556249B2 (en) 2010-02-18 2017-01-31 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
EP2538981B1 (en) 2010-02-23 2017-12-20 F. Hoffmann-La Roche AG Compositions and methods for the diagnosis and treatment of tumor
WO2011139985A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
US10208129B2 (en) 2010-12-06 2019-02-19 National Research Council Of Canada Antibodies selective for cells presenting ErbB2 at high density
EP2655413B1 (en) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
KR20140057326A (ko) 2011-08-17 2014-05-12 제넨테크, 인크. 뉴레귤린 항체 및 그의 용도
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
RU2019103083A (ru) 2011-11-30 2019-03-22 Дженентек, Инк. МУТАЦИИ ErbB3 ПРИ РАКЕ
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
EP2831115A1 (en) 2012-03-27 2015-02-04 F. Hoffmann-La Roche AG Diagnosis and treatments relating to her3 inhibitors
BR112015012644A2 (pt) 2012-11-30 2017-12-19 Hoffmann La Roche método para determinar a necessidade de um paciente com câncer, método de tratamento do câncer, composição farmacêutica, uso de um ácido nucleico ou anticorpo e kit;
US10675352B2 (en) 2014-02-14 2020-06-09 Centrose, Llc Extracellular targeted drug conjugates
EP3454863A1 (en) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
TW202344272A (zh) 2018-04-13 2023-11-16 美商建南德克公司 穩定抗cd79b免疫結合物調配物
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0444181B2 (en) * 1989-08-04 2010-11-24 Bayer Schering Pharma Aktiengesellschaft C-erbb-2 external domain: gp75

Also Published As

Publication number Publication date
ATE186219T1 (de) 1999-11-15
PT616812E (pt) 2000-04-28
DE69326937T2 (de) 2000-12-28
GR3032511T3 (en) 2000-05-31
EP0616812A1 (en) 1994-09-28
DE69326937D1 (de) 1999-12-09
ES2141128T3 (es) 2000-03-16
EP0616812B1 (en) 1999-11-03

Similar Documents

Publication Publication Date Title
DK0616812T3 (da) Kombination af antihormonforbindelser og bindingsmolekyler til behandling af cancer
BR0009505A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
BR9808881A (pt) Compostos para imunoterapia de câncer de próstata e métodos para seu uso
BRPI0213223B8 (pt) polipeptídeo, dímero ou multímero, polinucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica, e, uso de uma composição
NO20061723L (no) Intercellulaert domene av HER-2/neu-protein for forhindring eller behandling av malignitet
CY1105475T1 (el) Συνθεσεις και μεθοδοι θepαπευτικης αγωγης νεοπλασματων
NO20003230D0 (no) Inhibering av RAF-kinase ved anvendelse av symmetrisk og usymmetrisk substituerte difenylureaforbindelser
ATE397621T1 (de) Hemmer der interaktion zwischen p53 und mdm2
TR200003879T2 (tr) İn vivo ışın tedavisine duyarlılaştırıcı özelliklere sahip farnesil protein transferaz inhibitörleri@
BR9908823A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
CY1109525T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΑ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2 ΚΑΙ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΜΕ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2
WO2004006842A3 (en) Combinations of drugs for the treatment of neoplasms
ATE556713T1 (de) Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
BR9907259A (pt) Compostos para terapia e diagnóstico de câncer de pulmão e processos para o seu uso
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
BR0209129A (pt) Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
BR0209127A (pt) compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
DE602004025726D1 (de) Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
BR9805544C1 (pt) Uso de um composto.
BR0306715A (pt) Métodos para diagnóstico e tratamento de tumores
DE69133068T2 (de) Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen
BR0308606A (pt) Derivados de hemiasterlina e usos destes
BR0209128A (pt) Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
BR9814419A (pt) "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
ES2155519T3 (es) Preparaciones inmunoterapeuticas que contienen gamma-globulinas para tratar enfermedades cancerosas.